Bradley J. Phd Bolzon Sells 400 Shares of I-Mab (NASDAQ:BDTX) Stock

I-Mab (NASDAQ:BDTX) Director Bradley J. Phd Bolzon sold 400 shares of I-Mab stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $33.11, for a total transaction of $13,244.00. Following the sale, the director now owns 10,178 shares of the company’s stock, valued at $336,993.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

I-Mab stock opened at $33.70 on Friday. The company has a market capitalization of $1.21 billion and a PE ratio of -1.98. The firm has a fifty day simple moving average of $30.20 and a two-hundred day simple moving average of $33.30. I-Mab has a twelve month low of $17.63 and a twelve month high of $46.25.

I-Mab (NASDAQ:BDTX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.03. As a group, analysts predict that I-Mab will post -2.11 earnings per share for the current year.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of I-Mab from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a report on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of I-Mab in a report on Wednesday, August 12th. Finally, BidaskClub raised shares of I-Mab from a “strong sell” rating to a “sell” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. I-Mab currently has an average rating of “Buy” and a consensus target price of $45.60.

I-Mab Company Profile

Black Diamond Therapeutics, Inc, a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

Further Reading: Support Level

Insider Buying and Selling by Quarter for I-Mab (NASDAQ:BDTX)

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with's FREE daily email newsletter.